Redesign Science

Redesign Science is a platform biotechnology company founded in 2017, specializing in computational drug discovery for small molecule therapeutics targeting dynamic protein interactions, particularly in oncology and inflammatory diseases. It uses its NUVO™ platform, integrating physics-based molecular dynamics simulations with generative AI, to identify novel drug sites on challenging ("undruggable") targets and advance an internal pre-clinical pipeline alongside co-development partnerships. The company remains privately held and active, headquartered in New York, NY, with ~$17M raised from notable VC investors; no public clinical programs, acquisitions, or revenue data available.